US00548A1060

— Total revenues expected to be $20.8 million for fourth quarter 2020 and $74.2 million for full year 2020 — — Product sales of GOCOVRI® expected to be $19.8 million for fourth quarter 2020 and $71.2 million for full year 2020 — Published on : http://www.globenewswire.com/news-release/2021/01/13/2158021/0/en/Adamas-Provides-Preliminary-Fourth-Quarter-and-Full-Year-2020-Total-Revenues-and-Key-Business-Drivers-for-2021.html…

More

EMERYVILLE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, Chief Executive Officer, will participate in a fireside chat at the ICR Conference 2021, being held January 11-14, 2021. Published on : http://www.globenewswire.com/news-release/2021/01/07/2155291/0/en/Adamas-to-Present-at-Upcoming-ICR-Conference.html…

More

Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Royalty-Backed Loan Agreement Amendment Effective with OSMOLEX ER Acquisition Published on : http://www.globenewswire.com/news-release/2021/01/05/2153573/0/en/Adamas-Completes-Acquisition-of-OSMOLEX-ER.html…

More